Wednesday, 4 March 2009

Drug firm leaves R & D to others

据 wsj Mar 2,2009 报导.Valeant pharmaceuticals prefers to forgo the risk,grow through acquisitions. R & D 'is a high-risk bet,and the fact is we fail more often that we succed' says Robert Ingram, Valeant's lead director.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)